Portfolio company Synnovation Therapeutics acquired by Novartis for its pan-mutant selective PI3Kα inhibitor program.
Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets
Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets. We are dedicated to the discovery and development of best-in-class therapeutics that can improve the lives of people living with cancer.